The Valley Desk

NCT03401788 · Interventional trial

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Overall registry status Active not recruiting

Phase 2

Conditions VHL - Von Hippel-Lindau Syndrome, VHL Gene Inactivation, VHL Gene Mutation, VHL Syndrome, VHL-Associated Clear Cell Renal Cell Carcinoma, VHL-Associated Renal Cell Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov